Pfizer (NYSE:PFE) Trading 1.2% Higher – Still a Buy?

Pfizer Inc. (NYSE:PFE)’s stock price rose 1.2% during mid-day trading on Monday . The stock traded as high as $24.72 and last traded at $24.4610. Approximately 42,686,866 shares traded hands during trading, an increase of 0% from the average daily volume of 42,519,129 shares. The stock had previously closed at $24.17.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer won FDA approval for a platinum-free Padcev-Keytruda regimen for muscle-invasive bladder cancer, expanding the treatment to a broader patient group and strengthening its oncology growth story. Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen
• Positive Sentiment: Analysts and commentators are increasingly focused on Pfizer’s oncology pipeline and Seagen integration, suggesting the company could create long-term value if its cancer franchise keeps expanding. Pfizer Vs. Amgen: Bet That Pfizer’s Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen
• Positive Sentiment: Pfizer’s oncology growth story is also being highlighted ahead of Q2 results, with cancer-drug sales, biosimilars and pipeline updates seen as possible offsets to declines in older therapies. Here’s How Pfizer’s Oncology Growth Story Looks Ahead of Q2 Results
• Neutral Sentiment: Pfizer remains a high-yield dividend stock, which supports investor interest, but some coverage questions whether the payout is sustainable if earnings remain under pressure. Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried?
• Neutral Sentiment: Pfizer has also been discussed as a value stock, with recent analyst note changes keeping the share price target range in view but not materially changing the near-term story. Analyst price target updates on Pfizer
• Negative Sentiment: Near-term expectations for Pfizer’s next earnings report are less upbeat, with Wall Street looking for a double-digit decline in profit, which could weigh on sentiment if results disappoint. Here’s What to Expect From Pfizer’s Next Earnings Report
• Negative Sentiment: Broader coverage on drug-pricing deals and policy pressure continues to highlight an overhang for large drugmakers like Pfizer, even if pipelines remain the bigger long-term driver. Donald Trump’s Drug-Pricing Deals Are Reshaping Big Pharma — Here’s What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. HSBC lowered Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the company from $32.00 to $28.00 in a research report on Monday, July 6th. Citigroup lifted their price objective on Pfizer from $26.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 29th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Royal Bank Of Canada raised shares of Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 target price for the company in a research report on Tuesday, June 9th. Finally, Bank of America dropped their price target on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $28.50.

Pfizer Stock Performance

The company has a 50-day moving average price of $25.28 and a two-hundred day moving average price of $26.18. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The stock has a market capitalization of $138.17 billion, a P/E ratio of 18.51 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 7.1%. Pfizer’s dividend payout ratio (DPR) is 131.30%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Norges Bank acquired a new stake in Pfizer in the fourth quarter valued at approximately $1,830,986,000. Morgan Stanley raised its position in shares of Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after purchasing an additional 14,342,946 shares during the period. Bank of New York Mellon Corp raised its position in shares of Pfizer by 38.9% during the fourth quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after purchasing an additional 13,581,757 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Pfizer by 577.5% in the 4th quarter. Janus Henderson Group PLC now owns 8,786,084 shares of the biopharmaceutical company’s stock worth $218,817,000 after purchasing an additional 7,489,189 shares in the last quarter. Finally, Capital World Investors grew its position in Pfizer by 51.5% in the 4th quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock valued at $533,704,000 after purchasing an additional 7,287,194 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.